With data from a second phase 3 trial, AstraZeneca has finally convinced FDA regulators that its new COPD offering deserves a place on the U.S. market just as a competitor from GlaxoSmithKline does.
After AstraZeneca’s fast-growing respiratory biologic Fasenra failed to move the needle in a COPD trial, hopes were directed to its three-in-one inhaler Breztri. But the potential challenger to ...
If you have chronic obstructive pulmonary disease (COPD)—an umbrella term for several lung diseases, including emphysema, chronic bronchitis and some forms of asthmatic bronchitis—you know what a game ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results